CyndRx has begun enrollment in the SEAL TO HEAL U.S. IDE clinical trial to assess the safety and effectiveness of the AbsorbaSeal™ 5.6.7F Vascular Closure Device. The AbsorbaSeal™ 5.6.7F vascular [...]
CyndRx, LLC Receives Full FDA Approval of Investigational Device Exemption (IDE) to Initiate a U.S. Pivotal Trial for the AbsorbaSeal™ 5.6.7F Vascular Closure Device The AbsorbaSeal™ 5.6.7F Vascular Closure Device [...]
CyndRx, LLC Finalizes CE Mark Trial with Strong Clinical Outcomes using AbsorbaSeal™ Vascular Closure Device Photo: AbsorbaSeal™ 5.6.7F Vascular Closure Device CyndRx, LLC, a medical device company focused on improving [...]
CyndRx, LLC Announces Completion of Enrollment in the AbsorbaSeal™ Vascular Closure Device CE Mark Trial CyndRx, LLC, a medical device company focused on improving vascular closure, announced completion of enrollment [...]
CyndRx, LLC Enrolls First Patients in the AbsorbaSeal™ Vascular Closure Device CE Mark Trial Study to Support European Approval of the AbsorbaSeal™ 5.6.7F Vascular Closure Device (VCD) CyndRx, LLC, a [...]
CyndRx, LLC has initiated training for sites that will participate in the multi-center trial of the AbsorbaSeal™ 5.6.7F Vascular Closure Device (VCD) to support CE Mark approval. CyndRx, LLC announced [...]